Prehospital Recognition and Identification of Unspecific Symptoms

NCT03089359 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 414

Last updated 2021-03-25

No results posted yet for this study

Summary

This study evaluates the predictive value of soluvent urokinase plasminogen activator receptor (suPAR) and lactate with respect to serious conditions among patients presenting to the EMS with unspecific symptoms.

Conditions

  • Serious Condition
  • Morality

Sponsors & Collaborators

Principal Investigators

  • Katarina Bohm, PhD · Karolinska Institutet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-04
Primary Completion
2021-03-23
Completion
2021-03-23

Countries

  • Finland
  • Sweden

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03089359 on ClinicalTrials.gov